Is docetaxel-free interval a predictive factor for castration-resistant prostate cancer?

Area of Science:

• Oncology
• Urology
• Medical Research

Background:

• Prostate cancer (PCa) is a leading cause of cancer death in men, often requiring palliative care in advanced stages.
• Castration-resistant prostate cancer (CRPC) presents significant treatment challenges, necessitating predictive indicators for therapy selection.
• Docetaxel (Dx) is a common chemotherapy for CRPC, but its effectiveness and impact on subsequent treatments require further investigation.

Purpose of the Study:

• To evaluate the docetaxel-free interval as a predictive biomarker in castration-resistant prostate cancer (CRPC).
• To determine if the docetaxel-free interval influences the efficacy of subsequent androgen receptor axis targeted (ARAT) therapies.
• To explore the potential for classifying CRPC based on docetaxel sensitivity.

Main Methods:

• Retrospective review of 104 CRPC patients treated with docetaxel (Dx) followed by ARAT therapy (abiraterone or enzalutamide).
• Analysis of progression time after Dx therapy and its correlation with response duration to sequential ARAT treatment.
• Statistical analysis to assess the relationship between the docetaxel-free interval and ARAT treatment response.

Main Results:

• A statistically significant relationship was observed between the docetaxel-free interval and the duration of response to ARAT therapy (p<0.001).
• Patients with a docetaxel-free interval of less than 9 months had a response time of less than 10.5 months to ARAT treatment.
• This suggests that the docetaxel-free interval can predict treatment outcomes in CRPC.

Conclusions:

• The docetaxel-free interval serves as a valuable predictive factor for castration-resistant prostate cancer (CRPC).
• CRPC can be categorized into docetaxel-sensitive or docetaxel-resistant disease based on this interval.
• This classification can inform clinical decisions regarding subsequent treatment strategies for advanced prostate cancer.